Form 4: Precision BioSciences CRO Reports RSU Vesting, Tax-Related Stock Sale

Precision BioSciences' Chief Research Officer, J. Jefferson Smith, reported the vesting of restricted stock units and a subsequent sell-to-cover transaction for tax obligations.

Summary

• J. Jefferson Smith, Chief Research Officer of Precision BioSciences Inc. (DTIL), reported transactions related to his beneficial ownership.
• On January 20, 2026, 2,500, 10,447, and 16,219 Restricted Stock Units (RSUs) vested, converting into common stock.
• Following these vestings, Smith's direct beneficial ownership increased to 120,384 shares.
• On January 21, 2026, 10,200 shares of common stock were disposed of at a price of $4.03 per share.
• This disposition was a "sell-to-cover" transaction, executed under a Rule 10b5-1 plan adopted on April 25, 2024, solely to cover tax withholding obligations related to the RSU vesting.
• After the sell-to-cover, Smith's direct beneficial ownership stands at 110,184 shares.
• Smith also holds 7,931 shares indirectly through a Charitable Remainder Unitrust.
• His total beneficial ownership includes 3,413 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan at a weighted average price of $5.74 per share.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation (RSU vesting and a tax-related sell-to-cover). These are expected events and do not indicate a significant positive or negative shift in the company's operational or financial performance.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates continued compensation and retention of a key executive.
• The transactions were executed under a pre-arranged Rule 10b5-1 plan, demonstrating planned and transparent executive compensation management.

Negatives

• A portion of vested shares was sold, reducing the executive's direct ownership, although this was explicitly for tax purposes.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports insider transactions.

Management Comments

• "The sales were effected pursuant to a Rule 10b5-1 plan adopted on April 25, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees."

Industry Context

This filing is a routine disclosure of insider equity transactions, specifically related to executive compensation. It does not provide information that directly relates to broader industry trends or competitive landscape. Such transactions are common across publicly traded companies as part of executive compensation and tax planning.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a standard practice across many industries, particularly in biotechnology and life sciences, aligning executive incentives with long-term shareholder value.
• The adoption of a Rule 10b5-1 plan for pre-scheduled stock transactions, including "sell-to-cover" for tax obligations, is a widely accepted corporate governance practice. This helps executives manage their equity holdings while mitigating concerns about insider trading, aligning with best practices for transparency and compliance.
• The reported transactions are consistent with typical executive compensation and tax management strategies observed in comparable biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders: The report provides transparency regarding executive equity ownership and compensation, which is generally positive for investor confidence. The sell-to-cover transaction is a routine event and not indicative of a lack of confidence.
• Employees: The RSU vesting demonstrates the company's commitment to its executive compensation structure, which can positively influence employee morale and retention, particularly for key personnel.

Next Steps

• Future RSU vesting installments are scheduled for grants made on April 18, 2024, and August 22, 2024, with vesting beginning on January 20, 2025, in three substantially equal annual installments.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of Restricted Stock Units (RSUs) and a subsequent "sell-to-cover" transaction for tax purposes, executed under a pre-arranged Rule 10b5-1 plan. These are expected events and do not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a "hold" recommendation is appropriate as the filing itself does not present a catalyst for significant price movement or a re-evaluation of the company's fundamentals.

Keywords

Precision BioSciences, DTIL, J. Jefferson Smith, Chief Research Officer, Form 4, SEC filing, Restricted Stock Units, RSU vesting, Sell-to-cover, Rule 10b5-1 plan, Insider transaction, Equity compensation